One common theme of the
Lewis Blackman and
Michael Skolnik stories is that of a surgeon who neglects to engage in a proper informed consent with a patient about the relative risks and benefits of a new surgical procedure. That both cases end in tragedy is immensely sad, but it would be a mistake to view the cases as isolated examples. Indeed, they are representative of a broader violation of the public trust. As
I have noted with regard to the Blackman case:
[These are] cases in which an ambitious surgeon with a new technique or using new
equipment takes on a case without providing full disclosure to the
patient or family about the potential for increased risk compared to
proven methods. Some hospitals are complicit in promoting such
"experiments" by not requiring IRB approval (i.e., human subjects
review) or approval by some peer ethics committee. They (surgeon and
hospital) do this for business reasons, to offer themselves in a
competitive marketplace as having "the latest and the best." The
surgeon then writes an article proclaiming the success of the new
procedure, but that article seldom or ever looks at the long-term
consequences, and it never indicates why--in terms of risk to the
patient--the new procedure went forth in the first place.
Today, I summarize another case that, to me, raises similar concerns. I offer it so that you can make your own judgment, and I welcome your comments below.
The surgery occurred several years ago. Of course, I have no access to the detailed patient records. I only have materials that are in the public domain, but they offer a story worth telling.
There is perhaps no procedure more compelling than a living related liver donation, and I count the surgeons who carry out these procedures as nothing short of heroic.
USCF notes:
In living donor liver transplantation, a piece of liver is removed
from a living donor and transplanted into a recipient. The procedure,
performed after the diseased liver has been removed, is possible because
the liver regenerates or grows. The liver's unique ability to
regenerate itself — combined with technological advances — allows more
people to be donors.
Regeneration happens over a short period, possibly days to weeks and
certainly within eight weeks. When surgeons remove a piece of the
donor's liver, the part that remains grows back quickly to its original
size.
That simple description belies the complexity and risks of this procedure, not only for the recipient, but also for the donor. Back in 2010, Dr. William F. Balistreri, Medical Director, Liver Transplantation Program, Cincinnati
Children's Hospital Medical Center,
noted (cites omitted):
Live donor liver transplantation, specifically, performance of a major
hepatectomy on a healthy individual who has no medical indication other
than offering an allograft liver for the recipient, has long been viewed
with caution and skepticism.
Therefore, substantial efforts are expended to ensure the safety and
long-term well being of the donor. The best outcomes for both donors and
recipients have been maximized via technical refinements, innovative
pre- and postoperative management strategies, and careful follow-up.
The estimated risk of mortality is 0.5 to 1%. Overall donor morbidity is high, estimated to be roughly 35%. This
is usually related to the surgical incision and the possibility of
blood clots; other reported problems include bleeding, infection, bile
leaks, damage to the bile tree, or risks from anesthesia. Donors have
reported chronic problems, including bile strictures, reoperations, and
chronic pain.
In summary, the risk of dying from living liver donor surgery may be as
high as 0.5% when donating the right lobe. If all complications are
included, 1 of every 3 donors will experience a complication; most are
considered minor or have no permanent sequelae. Thus, centers must carefully weigh the risks against the benefits.
Likewise, potential living liver donors should balance the decision to
donate with the advice of family, friends, an independent donor
advocate, and the medical/surgical team. As stated by Marsh and
colleagues, "no matter how carefully right lobar living donor
transplantation is applied, the historical verdict on the ethics of this
procedure may be harsh."
Dr. Balisteri's remarks relate to the general case. Adding the use of robotic surgery techniques increases that risk, as noted in the textbook
Transplantation of the Liver, by Ronald W. Busuttil, Goran B. Klintmalm (page 734):
So, now let's go back to 2008. What more compelling story can we imagine than a brother donating a portion of his liver to his sibling? Titled
"True Example of Brotherly Love,"
Channel 13 reported:
Finding the perfect match means accepting that the right person may
never come along. But for one Rockford area family the right donor is
not only a perfect match, but a testament of brotherly love. The two
underwent a first in the medical world.
It's called the da Vinci Robotic Surgical System and now the University
of Illinois Medical Center in Chicago completed the world's first
minimally invasive liver resection.
This is basically bonding two
brothers in a very unique way.
Gary Tongue needed a living donor. Gary tells 13 News, "One day he
showed up and wanted to know about the live donor transplant thing."
"He" is Charles Tongue, Gary Tongue's half-brother. Gary had liver
cancer which to him was a death sentence until both families started
exploring.
Charles says, "You have to be pretty much a perfect match. Weight,
height, everything has to be about right."
With the most important match being blood-type. Dr. Enrico Benedetti
completed the procedure by taking 60% of Charles' liver to replace the
diseased liver in Gary. Doctors ended up finding five tumors saying it
was worse then they thought.
Gary states, "It was rough for awhile. It's one heck of a surgery to go
through, but I think it's all going to worth it."
Both came home last week and continue to recover together.
Charles states, "It's a big weight off his shoulders that you know he's
got it and things are working good and I know he's going to live now."
Gary continues on by saying "You really have to love someone to do what
he did. By giving me a piece of that. It saved my life is what he did."
The publicity continued on a
liver failure support group site, with the following headlines:
Surgeons used the Da Vinci System to perform the first ever robotic liver transplant, done at the UIC Medical Center.
Team performs world's first robotic liver transplant
The story continues (emphasis not added):
Transplant surgeons performed the world's first minimally-invasive
liver resection for living-donor transplantation last week at the University of Illinois Medical Center.
Gary Tongue, a Rockford area man, was the first to receive this
transplantation performed by robotic surgical techniques. Charles
Tongue, his half-brother, was the donor of the liver. When Charles
realized how high his half-brother's risks were, Gary decided he could
donate a portion of his liver to him and potentially save his life.
UIC's chief of general surgery, Dr. Pier Cristoforo Giulianotti and his colleague Dr. Fabio Sbrana, used the da Vinci Robotic Surgical System
to remove 60 percent of Charles Tongue's liver. Surgeons then placed
Charles' liver into his half-brother, Gary. The process would have
included a long incision covering the entire upper abdomen that is
required to remove the right lobe of the liver. UIC's surgical team,
aided by the da Vinci Robotic System, used a different approach. They
completed the procedure through four small incisions. They then removed
the lobe through a three-inch incision in the lower abdomen to minimize
any postoperative pain that patients might experience.
According
to Giulianotti, "this transplant could be a turning point event
heralding a new era in living-donor liver transplantation. The
possibility of offering the donor a perfect minimally-invasive
operation, increasing the accuracy of the resection while minimizing
operative risk and blood loss, is a major step forward."
Benedetti further explained transplantations by clarifying the risks
involved. "We discuss openly the risk of the donor procedure with
prospective donors and we routinely involve an ethical committee
representative to ensure that the potential donor has fully understood
the risks," said Benedetti. "We quote a risk of mortality of 0.2-0.5
percent, according to the current Literature data. We also quote a risk
of about 30 percent of complications, including potential for bleeding,
leak of bile, infection etc. Usually after resection the liver will
regenerate to full size within five to seven weeks."
"Living
donor liver transplantation is a life-saving option, especially for a
patient with liver cancer," Benedetti said, "but it's very important
that the donor understands the risks and be healthy enough to be a good
candidate." He pointed out that in order to do this surgery doctors must
operate on a healthy man to remove much of his liver. In the Tongues'
case, Charles didn't hesitate to offer his liver to his half-brother,
Gary. "I couldn't ask Charles to do this, but he insisted," said Gary.
The same story showed up on
this investor website.
In 2011, the case was summarized by the surgeons and others in an article in
Transplant International. Of relevance to us here, the article stated:
The possibility of using minimally invasive robotic
technique for RLDH was discussed during the process of
informed consent. All technical aspects and safety issues
were explained, emphasizing the fact that the robotic
approach had never been used before for RLDH. Subsequently, the ethics committee of the hospital evaluated
the donor in accordance with the previously published
standard protocol [6]. The donor agreed to proceed with
the planned RLDH using robotic technique.
The "previously published standard protocol" is dated
2005. Its focus is on the general ethical standards that apply to liver transplants, well before any application of robotic surgery to this kind of procedure. And we are left with no information as to how the surgeon explained the risk of the robotic technique to the patient, or how the surgeon explained why use of the robotic technique would be superior to standard procedures.
Of particular note, the authors acknoweldge that "the length of surgery was longer than that normally required for open right donor hepatectomy," but then state that "it must be considered that the complicated venous anatomy prolonged the total operating time."
I can't evaluate the latter clause, but my understanding from experts in the field is that the 8-hour duration of this case was considerably longer than a standard open donor hepatectomy, which is usually 5 to 6 hours.
Years later, the April 2015
Annals of Surgery "Recommendations for Laparoscopic Liver Resection" (
Volume 261, Number 4, at page 623) notes that the quality of evidence--which presumably includes the above article--that the outcomes of robotic liver resections "are superior or not inferior to other techniques" is "low" and that the procedure should still be considered in
the stage of development that requires institutional ethical approval and detailed reporting of results and maintenance of
a registry:
It is hard to go back to 2008 and imagine what was in the mind of the surgical team for this case. The issue is complicated by the intense desire of this hospital to be known as a center for robotically assisted surgery and the surgical team's
long-term relationship with the company manufacturing this equipment. (Interpretations today are also complicated by their
financial relationships with the company.)
In my mind, the team should have been required to get
IRB approval (a standard for objective review of human subjects experiments) for this case. It was a new technology being applied to a live donor who had little to gain
and well documented risks of morbidity and mortality. Approval of the
usual ethics committee for live donors was likely inadequate when adding on the unknown risk of robotic surgery. The biggest risk of
doing these cases in a minimally invasive way is that if you get into
serious (and often sudden) massive bleeding you won't be able to
open and control the bleeding quickly enough. The patient could die or have severe hemorrhage before it is controlled. There is also the additional risk of a longer time under anaesthesia. An IRB review by
uninvolved individuals with a variety of backgrounds would have balanced those potential risks against the additional scientific and clinical knowledge that could result from the experiment.
In summary, new surgical approaches like this--where there will not likely be randomized trials but where the risk is high--suggest that IRB approval should be part of
the development of the new technology. Absent that, the patient is held hostage to the possibility that the surgeon's personal judgment--no matter how well intentioned--might be colored by commercial strategies of that doctor, the hospital, and the equipment supplier.